PureTech Health PLC - Asset Resilience Ratio
PureTech Health PLC (PRTC) has an Asset Resilience Ratio of 4.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PureTech Health PLC current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how PureTech Health PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of PureTech Health PLC.
Liquid Assets Composition Over Time
This chart breaks down PureTech Health PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PRTC current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $24.83 Million | 4.64% |
| Total Liquid Assets | $24.83 Million | 4.64% |
Asset Resilience Insights
- Limited Liquidity: PureTech Health PLC maintains only 4.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PureTech Health PLC Industry Peers by Asset Resilience Ratio
Compare PureTech Health PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for PureTech Health PLC (2012–2025)
The table below shows the annual Asset Resilience Ratio data for PureTech Health PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.64% | $24.83 Million | $534.71 Million | -9.74pp |
| 2024-12-31 | 14.38% | $86.67 Million | $602.63 Million | -5.23pp |
| 2023-12-31 | 19.61% | $136.06 Million | $693.97 Million | -8.89pp |
| 2022-12-31 | 28.50% | $200.23 Million | $702.65 Million | +28.63pp |
| 2021-12-31 | -0.14% | $-1.28 Million | $946.01 Million | +0.04pp |
| 2020-12-31 | -0.17% | $-1.70 Million | $989.99 Million | -3.37pp |
| 2019-12-31 | 3.20% | $30.09 Million | $941.18 Million | -27.10pp |
| 2018-12-31 | 30.29% | $133.83 Million | $441.76 Million | -4.14pp |
| 2017-12-31 | 34.43% | $117.03 Million | $339.85 Million | -39.01pp |
| 2016-12-31 | 73.44% | $219.41 Million | $298.75 Million | +18.42pp |
| 2015-12-31 | 55.02% | $179.78 Million | $326.75 Million | +54.51pp |
| 2014-12-31 | 0.51% | $1.17 Million | $228.03 Million | -10.41pp |
| 2013-12-31 | 10.92% | $1.83 Million | $16.77 Million | +4.79pp |
| 2012-12-31 | 6.13% | $1.18 Million | $19.18 Million | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more